100
Participants
Start Date
January 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
April 30, 2013
Ocriplasmin
ocriplasmin intravitreal injection (125 µg)
Sham injection
Sham injection
Allegheny Ophthalmic & Orbital Associates, PC, Pittsburgh
Southeast Retina Center, PC, Augusta
Center for Retina and Maculla Disease, Winter Haven
Southeastern Retina Associates, Kingsport
VitreoRetinal Surgery, PA, Minneapolis
Black Hills Regional Eye Institute, Rapid City
Centre Ophtalmologique d'Imagerie et de Laser, Paris
Valley Retina Institute, McAllen
Retinal Consultants of Houston,, Houston
University of Colorado Denver, Aurora
Augenklinik der Ludwig Maximilians Universität München, München
Retina-Vitreous Associates Medical Group, Beverly Hills
Retinal Consultants Medical Group, Sacramento
Retina-Vitreous Center, PA, New Brunswick
U.Z. Leuven St. Rafaël Hospital, Leuven
Rabelais Ophthalmologic Center, Lyon
Centre Paradis-Monticelli, Marseille
Centre Ophtalmologique de L'Odeon, Paris
Universität Bonn Augenklinik, Bonn
Universität Lübeck Universitätsklinikum Schleswig-Holstein, Lübeck
Klinik für Augenheilkunde, Universitätsklinikum Gießen, Standort Marburg, Marburg
"University of Milan Department of Clinical Science Luigi Sacco", Milan
Largo Agostino Gemelli (University Hospital) Institute of Ophthalmology, Rome
Frimley Park Hospital, Frimley
Royal Liverpool & Broadgreen Hospital, Liverpool
Moorfields Eye Hospital, London
Wolverhampton Eye Infirmary New Cross Hospital, Wolverhampton
Lead Sponsor
ThromboGenics
INDUSTRY